Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash from Financing Activities (2020 - 2026)

Atea Pharmaceuticals' Cash from Financing Activities history spans 7 years, with the latest figure at $257000.0 for Q1 2026.

  • Quarterly Cash from Financing Activities rose 174.06% to $257000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$25.1 million through Mar 2026, down 10830.87% year-over-year, with the annual reading at -$25.7 million for FY2025, 9742.32% down from the prior year.
  • Cash from Financing Activities came in at $257000.0 for Q1 2026, up from -$11.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $257000.0 in Q1 2026 to a low of -$14.1 million in Q2 2025.
  • The 5-year median for Cash from Financing Activities is $132000.0 (2022), against an average of -$2.5 million.
  • Year-over-year, Cash from Financing Activities plummeted 9762.39% in 2025 and then soared 174.06% in 2026.
  • Atea Pharmaceuticals' Cash from Financing Activities stood at $147000.0 in 2022, then tumbled by 37.41% to $92000.0 in 2023, then increased by 27.17% to $117000.0 in 2024, then tumbled by 9762.39% to -$11.3 million in 2025, then soared by 102.27% to $257000.0 in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Cash from Financing Activities are $257000.0 (Q1 2026), -$11.3 million (Q3 2025), and -$14.1 million (Q2 2025).